Developing a physiologically based approach for modeling plutonium decorporation therapy with DTPA

References

• Bailey BR, Eckermann KF, Townsend LW. 2003. An analysis of a puncture wound case with medical intervention. Radiat Prot Dosim 105:509–512.
   PubMed Web of Science ®Google Scholar
• Barrett PH, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, Foster DM. 1998. SAAM II: Simulation, analysis and modeling software of tracer and pharmacokinetic studies. Metabolis 47:484–492.
   PubMed Web of Science ®Google Scholar
• Breustedt B, Blanchardon E, Berard P, Fritsch P, Giussani A, Lopez MA, Luciani A, Nosske D, Piechowski J, Schimmelpfeng J, Sérandour AL. 2009. Biokinetic modelling of DTPA decorporation therapy: The CONRAD approach. Radiat Prot Dosim 134:38–48.
   PubMed Web of Science ®Google Scholar
• Breustedt B, Blanchardon E, Berard P, Fritsch P, Giussani A, Lopez MA, Luciani A, Nosske D, Piechowski J, Schimmelpfeng J, Sérandour AL. 2010. The CONRAD approach to biokinetic modeling of DTPA decorporation therapy. Health Phys 99:547–552.
   PubMedGoogle Scholar
• Bulman RA. 1980. Some aspects of the bioinorganic chemistry of the actinides. Coordin Chem Rev 31:221–250.
   Web of Science ®Google Scholar
• Duffield J, Taylor DM, Proctor SA. 1986. The binding of plutonium to transferrin in the presence of tri-n-butyl phosphate or nitrate and its release by diethylenetriaminepenta-acetate and the tetrameric catechoylamide ligand LICAMC(C). Int J Nucl Med Biol 12:483–487.
   PubMedGoogle Scholar
• Durbin PW. 1972. Plutonium in man: A new look to old data. In: Stover BJ, Jee WSS, editors. Radiobiology of plutonium. Salt Lake City: JW Press. pp 469–530.
   Google Scholar
• Durbin PW. 2010. Actinides in animals and man. In: Morss LR, Edelstein NM, Fuger J, editors. The chemistry of actinide and transactinide elements. 4th ed. Dordrecht: Springer. pp 3339–3440.
   Google Scholar
• US Food and Drug Administration (FDA). 2004. Press release P04-78. Available from: http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm130312.htm
   Google Scholar
• Fritsch P, Grappin L, Guillermin AM, Fottorino R, Ruffin M, Mièle A. 2007. Modelling of bioassay data from a Pu wound treated by repeated DTPA perfusions: Biokinetics and dosimetry approaches. Radiat Prot Dosim 127:120–124.
   PubMedGoogle Scholar
• Fritsch P, Sérandour AL, Grémy O, Phan G, Tsapis N, Abram MC, Renault D, Fattal E, Benech H, Deverre JR, Poncy JL. 2009. Simplified structure of a new model to describe urinary excretion of plutonium after systemic, liver or pulmonary contamination of rats associated with Ca-DTPA treatments. Radiat Res 171:674–686.
   PubMedGoogle Scholar
• Hall RM, Poda GA, Fleming RR, Smith JA. 1978. A mathematical model for estimation of plutonium in the human body from urine data influenced by DTPA therapy. Health Phys 34:419–431.
   PubMedGoogle Scholar
• Huebers H, Finch CA. 1987. The physiology of transferrin and transferrin receptors. Physiol Rev 67:520–582.
   PubMed Web of Science ®Google Scholar
• International Commission on Radiological Protection (ICRP). 1992. Publication 67. Age-dependent doses to members of the public from intake of radionuclides – Part 2: Ingestion dose coefficients. Annals ICRP 22(3–4).
   Google Scholar
• James AC, Sasser LB, Stuit DB, Glover SE, Carbaugh EH. 2007. USTUR whole body case 0269: Demonstrating effectiveness of i.v. Ca-DTPA for Pu. Radiat Prot Dosim 127:449–455.
   PubMed Web of Science ®Google Scholar
• Jech J, Andersen BV, Heid KR. 1972. Interpretation of human urinary excretion of plutonium for cases treated with DTPA. Health Phys 22:787–792.
   PubMedGoogle Scholar
• Kety S. 1942. The lead citrate complex ion and its role in the physiology and therapy of lead poisoning. J Biol Chem 14:181–192.
   Google Scholar
• La Bone TR. 1994. Evaluation of intakes of transuranics influenced by chelation therapy. In: Raabe OG, editor. Internal radiation dosimetry. Madison, WI: Medical Physics Publishing. pp 461–467.
   Google Scholar
• Langham WR, Bassett SH, Harris PS, Carter RE. 1950. Distribution and excretion of plutonium administered intravenously to man. Los Alamos Scientific Laboratory Report LA-1151. (Reprinted in Health Phys 38: 1031–1060, 1980)
   Google Scholar
• Leggett RW, Eckermann KF, Khokhryakhov VF, Suslova KG, Krahenbuhl MP, Miller SC. 2005. Mayak worker study: An improved biokinetic model for reconstructing doses from internally deposited plutonium. Radiat Res 164:111–122.
   PubMed Web of Science ®Google Scholar
• Lopez MA, Balásházy I, Bérard P, Blanchardon E, Breustedt B, Broggio D, Castellani CM, Franck D, Giussani A, Hurtgen C, James AC, Klein W, Kramer GH, Li WB, Marsh JW, Malatova I, Nosske D, Oeh U, Phan G, Puncher M, Telles PT, Schimmelpfeng J, Vrba T. 2011. EURADOS coordinated action on research, quality assurance and training of internal dose assessments. Radiat Prot Dosim 144: 349–352.
   PubMedGoogle Scholar
• Luciani A. 2002. Plutonium biokinetics in human body. FZKA 6748. Karslruhe: Forschungszentrum Karlsruhe GmbH. ISSN 0947–8620.
   Google Scholar
• Luciani A, Polig E. 2000. Verification and modification of the ICRP-67 model for the plutonium dose calculation. Health Phys 78:303–310.
   PubMedGoogle Scholar
• Schimmelpfeng J. 2009. Physiology-based modelling in radiation research: The biokinetics of plutonium. Radiat Prot Dosim 136:74–81.
   PubMedGoogle Scholar
• Sérandour AL, Grémy O, Fréchou M, Renault D, Poncy JL, Fritsch P. 2008. In vitro and in vivo assessment of plutonium speciation and decorporation in blood and target retention tissues after a systemic contamination followed by an early treatment with DTPA. Radiat Res 170:208–215.
   PubMedGoogle Scholar
• Stather JW, Smith H, Bailey MR, Birchall A, Bulman RA, Crawley FE. 1983. The retention of 14C-DTPA in human volunteers after inhalation or intravenous injection. Health Phys 44:45–52.
   PubMed Web of Science ®Google Scholar
• Stradling GN, Taylor DM. 2005. Decorporation of radionuclides. In: Kaul A, Becker D, editors. Landolt Börnstein Group VIII Advanced materials and technologies. Vol. 4. Radiological protection. Berlin: Springer. pp 295–328.
   Google Scholar
• Talbot RJ, Newton D, Warner AJ. 1993. Metabolism of injected plutonium in two healthy men. Health Phys 65:41–46.
   PubMedGoogle Scholar
• Tancock NP, Taylor NA. 1993. Derivation of a new expression to describe the urinary excretion of plutonium by man. Radiat Prot Dosim 46:229–239.
   Google Scholar
• Volf V. 1978. Treatment of incorporated transuranium elements. IAEA Technical Report Series 184. Vienna: International Atomic Energy Agency.
   Google Scholar